Boston Children’s Hospital has been granted a patent for methods, compositions, and kits to treat ribosomal disorders like Diamond Blackfan anemia. The patent includes the use of novel compounds like RSK inhibitors and phenothiazine derivatives. GlobalData’s report on Boston Children’s Hospital gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Boston Children's Hospital, was a key innovation area identified from patents. Boston Children's Hospital's grant share as of April 2024 was 45%. Grant share is based on the ratio of number of grants to total number of patents.
Phenothiazine compound for treating ribosomal disorders
The granted patent (Publication Number: US11944625B2) discloses a series of phenothiazine compounds represented by Formula (I) and Formula (II). These compounds have various substituents on the phenothiazine ring, including alkyl, halo, hydroxy, amino, nitro, and carboxylic acid groups. The compounds are designed with specific structural features, such as X being sulfur and R1 being alkyl or alkylaryl groups like isopropyl or benzyl. Additionally, the patent covers pharmaceutical compositions containing these phenothiazine compounds or their pharmaceutically acceptable salts.
Furthermore, the patent includes specific examples of phenothiazine compounds like DB-4-083, DB-4-088-2, DB-4-087-2, and DB-4-089, each with distinct structures and substituents. These compounds are part of the claimed group of phenothiazines and can be used in pharmaceutical compositions for various applications. The compounds exhibit different properties based on the nature of the substituents, offering potential benefits in therapeutic interventions. The patent provides a detailed description of the chemical structures and methods for synthesizing these phenothiazine compounds, emphasizing their utility in pharmaceutical formulations.
To know more about GlobalData’s detailed insights on Boston Children's Hospital, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
